前列腺穿刺活检组织端粒酶活性检测及其临床意义

通过检测国人前列腺穿刺活检组织端粒酶活性,探讨其在前列腺癌诊断和预后的临床意义。20例前列腺癌标本和16例癌旁组织均来自前列腺穿刺活检,14例良性前列腺增生(BPH)标本取自前列腺摘除手术,均经病理证实。采用改良的TRAP-银染方法检测端粒酶活性,并进行半定量分析。结果20份前列腺癌标本中18份测得端粒酶活性(90％)。在16例癌旁前列腺组织中,64％(7/11)的前列腺上皮肉瘤(PIN)及40％(2/5)的癌旁BPH组织有端粒酶活性表达。14例BPH标本端粒酶活性均为阴性。18例前列腺癌阳性标本的端粒酶活性强度与肿瘤分级分期及PSA水平呈正相关。前列腺穿刺活检组织端粒酶活性检测可作为前列腺癌诊断的一项敏感性指标,其在前列腺癌预后中的价值有待于进一步的研究。

Detection of Telomerase Activity in Prostate Needle-Biopsy Samples

Telomerase activity in prostate needle-biopsy samples and benign prostatic hyperplasia were detected and its role in diagnosis and prognosis of prostate cancer were also evaluated. Tissue samples of which 20 prostate cancer tissues and 16 in adjacent were obtained from needle-biopsy of prostate guided by transrectal B ultrasonography, 16 benign prostatic hyperplasia tissues were obtained from opening prostatectomy. All samples were confirmed by pathologic examination. Telomerase activity was detected by modified PCR-based telomeric repeat amplication protocol (TRAP)-silver assay. Telomerase activity was detected in 18 of the 20 (90%) prostate cancers. In tissues adjacent to prostate cancer, telomerase activity was found in 7 of 11 (64%) prostatic intraepithelial neoplasia (PIN), 2 of 5 (40%) BPH. None of the tissue samples from patients only diagnosed BPH showed telomerase activity. The results indicated that telomerase activity may be an useful marker for prostate cancer and evaluating the biological malignant potentials.